Tejara Capital Ltd Acquires New Holdings in Certara, Inc. $CERT

Posted by Stanley Muller on Aug 21st, 2026

Tejara Capital Ltd purchased a new position in Certara, Inc. (NASDAQ:CERT – Free Report) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 1,292,721 shares of the company’s stock, valued at approximately $8,467,000. Certara comprises 3.5% of Tejara Capital Ltd’s holdings, making the stock its 9th largest position.

Several other large investors also recently added to or reduced their stakes in CERT. Granite Investment Partners LLC purchased a new stake in shares of Certara in the 1st quarter worth $2,130,000. Dimensional Fund Advisors LP lifted its position in Certara by 2.1% during the first quarter. Dimensional Fund Advisors LP now owns 8,562,508 shares of the company’s stock valued at $48,806,000 after purchasing an additional 175,024 shares in the last quarter. UBS Group AG lifted its position in Certara by 50.7% during the fourth quarter. UBS Group AG now owns 2,489,603 shares of the company’s stock valued at $21,933,000 after purchasing an additional 837,648 shares in the last quarter. Quantinno Capital Management LP grew its holdings in Certara by 412.5% during the first quarter. Quantinno Capital Management LP now owns 988,990 shares of the company’s stock valued at $5,637,000 after purchasing an additional 796,007 shares during the period. Finally, Renaissance Technologies LLC grew its stake in shares of Certara by 1,097.6% during the 1st quarter. Renaissance Technologies LLC now owns 354,500 shares of the company’s stock valued at $2,021,000 after acquiring an additional 324,900 shares during the period. 73.96% of the stock is currently owned by institutional investors.

Certara Trading Up 4.4%

CERT stock opened at $8.73 on Friday. Certara, Inc. has a twelve month low of $4.45 and a twelve month high of $13.88. The stock has a market capitalization of $1.33 billion, a price-to-earnings ratio of -19.40 and a beta of 1.44. The company has a quick ratio of 2.55, a current ratio of 2.55 and a debt-to-equity ratio of 0.30. The firm’s fifty day simple moving average is $7.05 and its two-hundred day simple moving average is $6.44.

Certara (NASDAQ:CERT – Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The company reported $0.08 EPS for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.01). The firm had revenue of $93.27 million for the quarter, compared to analysts’ expectations of $98.09 million. Certara had a positive return on equity of 3.86% and a negative net margin of 16.75%.Certara’s revenue for the quarter was down 10.8% on a year-over-year basis. During the same period in the prior year, the firm posted $0.07 earnings per share. As a group, analysts anticipate that Certara, Inc. will post 0.22 earnings per share for the current year.

Wall Street Analyst Weigh In

CERT has been the topic of a number of analyst reports. Morgan Stanley lowered their target price on shares of Certara from $11.00 to $10.00 and set an “equal weight” rating on the stock in a research note on Tuesday, May 12th. Robert W. Baird decreased their price target on Certara from $7.00 to $6.00 and set a “neutral” rating on the stock in a report on Tuesday, May 12th. Craig Hallum lowered their price objective on Certara from $10.00 to $8.00 and set a “hold” rating on the stock in a research report on Tuesday, May 12th. Weiss Ratings upgraded Certara from a “sell (e+)” rating to a “sell (d)” rating in a research report on Wednesday, August 5th. Finally, BMO Capital Markets cut their price objective on shares of Certara from $7.00 to $6.00 and set a “market perform” rating for the company in a report on Tuesday, May 12th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $8.28.

Get Our Latest Stock Analysis on Certara

About Certara

(Free Report)

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.